Why Is HALOZYME THERAPEUTIC (HALO) Stock Up Today?
By the Top Tier Newswire AI Desk · August 7, 2026 at 3:30 PM ET · reviewed against 19 wire stories
HALOZYME THERAPEUTIC (HALO) is up +19.35% in the latest session. Our newswire has captured 19 stories on HALO across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Halozyme Therapeutics stock surged 19.35% to $102.36 on Friday, marking a record high. The move followed the company’s strong second-quarter results, including a 48% increase in total revenue and expanded full-year guidance. Analysts raised price targets and upgraded the stock, reflecting optimism about the company’s Enhanze-tied product performance and new partnerships.
What Happened
Halozyme delivered a record-setting quarter with revenue growth and new high-profile collaborations. The company exceeded expectations in its collaboration goals and raised its full-year guidance. This performance was accompanied by a wave of analyst upgrades and higher price targets. Morgan Stanley, TD Cowen, and Wells Fargo all increased their price targets, with Leerink upgrading the stock to Outperform. The stock opened with a 6.1% gap up and continued to climb throughout the session, reaching an intraday high of $102.41.
What The Data Shows
The stock’s rally was driven by bullish Wall Street commentary and strong fundamental performance. The company reported a 39.1% year-to-date revenue increase and a net margin of 23.1%. The session saw 4.3 million shares traded, more than double the 3-month average. The stock closed near its intraday high, reflecting strong investor demand. Despite recent insider sales totaling $7.7 million in the last 90 days, the stock’s fundamentals and analyst support have propelled it to a new 52-week high.
What To Watch
With no upcoming earnings date provided, investors should monitor the breadth of analyst coverage and any further updates on the company’s collaboration progress. Continued strong performance could attract additional institutional interest.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
HALO · Aug 7 session (5-min) · +19.45% vs prior close · updated 8:56 PM ETAI sentiment, last 36h · averaged over 19 stories · 64/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoStocktwits NewsBULLISH 67Earnings
These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months
Natera and Halozyme Therapeutics saw gains above 15%, led by bullish Wall Street commentary after better-than-expected second-quarter results.
3d agoInvestors.comBULLISH 73Earnings
Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume
Halozyme stock rocketed to a record high Friday as its newer Enhanze-tied products starting driving incremental growth.
3d agoMarketChameleonBULLISH 76Earnings
HALO Raises the Bar: Record Results, Expanded Guidance, and Major Collaborations Define a Standout Quarter
August 7, 2026
Halozyme delivered a record-setting Q2 2026, with a 48% jump in total revenue, accelerated royalty growth, and new high-profile partnerships. The company raised its full-year guidance and exceeded its collaboration goals, setting the stage for continued momentum and highlighting long-term shareholder value.
3d agoThe FlyBULLISH 61Analyst
Halozyme price target raised to $105 from $93 at Morgan Stanley
3d agoThe FlyBULLISH 63Analyst
Halozyme Price Target Raised To 105 From 96 At Td Cowen
3d agoInvesting.com Analyst RatingsBULLISH 61Analyst
Citizens raises Halozyme stock price target to $93 on royalty growth
Citizens raises Halozyme stock price target to $93 on royalty growth
3d agoThe FlyBULLISH 67Analyst
Halozyme Price Target Raised To 95 From 75 At Wells Fargo
3d agoThe FlyBULLISH 61Analyst
Leerink Upgraded Halozyme To Outperform On Growth Market Leadership
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →